Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 13 studies | 47% ± 26% | |
retina horizontal cell | 6 studies | 24% ± 7% | |
GABAergic neuron | 6 studies | 56% ± 19% | |
type I pneumocyte | 6 studies | 25% ± 7% | |
neuron | 5 studies | 26% ± 8% | |
endothelial cell | 5 studies | 46% ± 18% | |
interneuron | 5 studies | 42% ± 15% | |
cardiac muscle cell | 5 studies | 53% ± 12% | |
oligodendrocyte precursor cell | 5 studies | 31% ± 11% | |
granule cell | 4 studies | 30% ± 14% | |
GABAergic interneuron | 3 studies | 26% ± 1% | |
amacrine cell | 3 studies | 28% ± 6% | |
epithelial cell | 3 studies | 30% ± 9% | |
glycinergic amacrine cell | 3 studies | 23% ± 5% | |
endothelial cell of lymphatic vessel | 3 studies | 21% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 97% | 1570.24 | 2558 / 2642 | 98% | 10.88 | 691 / 705 |
esophagus | 96% | 501.53 | 1391 / 1445 | 97% | 9.86 | 177 / 183 |
thymus | 100% | 1253.06 | 653 / 653 | 91% | 15.59 | 553 / 605 |
uterus | 94% | 613.51 | 159 / 170 | 94% | 8.17 | 432 / 459 |
lung | 85% | 361.88 | 492 / 578 | 96% | 8.04 | 1110 / 1155 |
ovary | 93% | 987.02 | 167 / 180 | 86% | 4.85 | 369 / 430 |
bladder | 86% | 395.67 | 18 / 21 | 92% | 7.35 | 463 / 504 |
skin | 95% | 462.60 | 1714 / 1809 | 74% | 6.12 | 350 / 472 |
breast | 71% | 279.05 | 328 / 459 | 82% | 6.28 | 919 / 1118 |
prostate | 71% | 240.40 | 173 / 245 | 81% | 3.77 | 406 / 502 |
kidney | 83% | 342.12 | 74 / 89 | 67% | 3.49 | 600 / 901 |
stomach | 53% | 264.71 | 190 / 359 | 87% | 5.38 | 249 / 286 |
intestine | 54% | 197.50 | 525 / 966 | 83% | 5.09 | 440 / 527 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.24 | 1 / 1 |
muscle | 100% | 2133.66 | 801 / 803 | 0% | 0 | 0 / 0 |
heart | 95% | 1442.72 | 819 / 861 | 0% | 0 | 0 / 0 |
pancreas | 5% | 14.25 | 18 / 328 | 84% | 4.16 | 149 / 178 |
tonsil | 0% | 0 | 0 / 0 | 89% | 6.97 | 40 / 45 |
blood vessel | 67% | 210.31 | 890 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 3% | 9.42 | 9 / 258 | 52% | 3.42 | 119 / 230 |
liver | 9% | 27.71 | 20 / 226 | 39% | 1.73 | 159 / 406 |
adipose | 44% | 212.07 | 529 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 28% | 0.97 | 8 / 29 |
peripheral blood | 18% | 115.95 | 165 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 15% | 0.48 | 12 / 80 |
spleen | 3% | 7.39 | 8 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0090279 | Biological process | regulation of calcium ion import |
GO_0099173 | Biological process | postsynapse organization |
GO_0003009 | Biological process | skeletal muscle contraction |
GO_0048741 | Biological process | skeletal muscle fiber development |
GO_0007206 | Biological process | phospholipase C-activating G protein-coupled glutamate receptor signaling pathway |
GO_0009967 | Biological process | positive regulation of signal transduction |
GO_0007216 | Biological process | G protein-coupled glutamate receptor signaling pathway |
GO_0051966 | Biological process | regulation of synaptic transmission, glutamatergic |
GO_0007623 | Biological process | circadian rhythm |
GO_0051262 | Biological process | protein tetramerization |
GO_0007268 | Biological process | chemical synaptic transmission |
GO_1902950 | Biological process | regulation of dendritic spine maintenance |
GO_0035094 | Biological process | response to nicotine |
GO_0051928 | Biological process | positive regulation of calcium ion transport |
GO_2001256 | Biological process | regulation of store-operated calcium entry |
GO_0048148 | Biological process | behavioral response to cocaine |
GO_0035418 | Biological process | protein localization to synapse |
GO_0051592 | Biological process | response to calcium ion |
GO_2001257 | Biological process | regulation of cation channel activity |
GO_0098978 | Cellular component | glutamatergic synapse |
GO_0005886 | Cellular component | plasma membrane |
GO_0043197 | Cellular component | dendritic spine |
GO_0043034 | Cellular component | costamere |
GO_0030018 | Cellular component | Z disc |
GO_0043198 | Cellular component | dendritic shaft |
GO_0044309 | Cellular component | neuron spine |
GO_0043025 | Cellular component | neuronal cell body |
GO_0030425 | Cellular component | dendrite |
GO_0005829 | Cellular component | cytosol |
GO_0014069 | Cellular component | postsynaptic density |
GO_0099524 | Cellular component | postsynaptic cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0060076 | Cellular component | excitatory synapse |
GO_0030424 | Cellular component | axon |
GO_0045177 | Cellular component | apical part of cell |
GO_0035256 | Molecular function | G protein-coupled glutamate receptor binding |
GO_0044877 | Molecular function | protein-containing complex binding |
GO_0099186 | Molecular function | structural constituent of postsynapse |
GO_0097110 | Molecular function | scaffold protein binding |
GO_0035591 | Molecular function | signaling adaptor activity |
GO_0044325 | Molecular function | transmembrane transporter binding |
GO_0031802 | Molecular function | type 5 metabotropic glutamate receptor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | HOMER1 |
Protein name | Homer protein homolog 1 (Homer-1) HOMER1F (Homer scaffold protein 1) Homer homolog 1 (Drosophila) |
Synonyms | SYN47 |
Description | FUNCTION: Postsynaptic density scaffolding protein. Binds and cross-links cytoplasmic regions of GRM1, GRM5, ITPR1, DNM3, RYR1, RYR2, SHANK1 and SHANK3. By physically linking GRM1 and GRM5 with ER-associated ITPR1 receptors, it aids the coupling of surface receptors to intracellular calcium release. May also couple GRM1 to PI3 kinase through its interaction with AGAP2. Isoform 1 regulates the trafficking and surface expression of GRM5. Isoform 3 acts as a natural dominant negative, in dynamic competition with constitutively expressed isoform 1 to regulate synaptic metabotropic glutamate function. Isoform 3, may be involved in the structural changes that occur at synapses during long-lasting neuronal plasticity and development. Forms a high-order complex with SHANK1, which in turn is necessary for the structural and functional integrity of dendritic spines (By similarity). Negatively regulates T cell activation by inhibiting the calcineurin-NFAT pathway. Acts by competing with calcineurin/PPP3CA for NFAT protein binding, hence preventing NFAT activation by PPP3CA . . |
Accessions | ENST00000535690.1 ENST00000334082.11 [Q86YM7-1] Q5U5K4 Q86YM7 Q86YM6 ENST00000508576.5 [Q86YM7-3] ENST00000282260.10 [Q86YM7-2] |